Extended Data Fig. 10: Evaluation of antifungal efficacy of mandimycin in different neutropenic mice models.
From: A polyene macrolide targeting phospholipids in the fungal cell membrane
A, Disseminated candidiasis model infected with MDR C. albicans BNCC 186382. n = 3 mice per group. Mandimycin was administrated through single subcutaneous injection. The fungal burden in lung tissue were counted and plotted. B, C, Mandimycin was administrated through single oral administration. The fungal burden in kidney (B) and lung tissue (C) were counted and plotted (n = 3 mice per group). D,E, In vivo antifungal efficacy of mandimycin in neutrophilic thigh infection mouse model infected with MDR C. albicans BNCC 186382 (D) and MDR C. auris BNCC 357785 (E). Mandimycin was administrated though subcutaneous injection. Fungal burden was counted after 24 h of treatment (n = 4 mice per group). F, Photos of wound size in the skin infection model. Significant differences between mouse groups were analyzed using one-way analysis of variance (ANOVA) (***P = 0.0005, ****P < 0.0001). Data are represented as mean ± SD in A–E.
